drug · small molecule

VANRAFIA

updated 5mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.

targets

Endothelin-1 receptor

all catalysts(0)

nothing on the calendar yet

News(2)

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
fiercebiotech · 20d ago
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal
stat · 1mo ago

brand

VANRAFIA

generic

ATRASENTAN HYDROCHLORIDE

MOA

12.1 Mechanism of Action Atrasentan is an ET A receptor antagonist (Ki = 0.034 nM) with >1800-fold selectivity for the ET A receptor compared to the endothelin type B receptor (Ki = 63.3 nM). Endothelin (ET)-1 is thought to contribute to the pathogenesis of IgAN via the ET A R.

indication

1 INDICATIONS AND USAGE VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on a reduction of proteinuria [see Clinical Studies (14.1)] . It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. VANRAFIA is an endothelin receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. ( 1 ) This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 5h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(2)

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.

fiercebiotech · 20d ago

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

stat · 1mo ago

VANRAFIA

🐶 often sniffed alongside

targets

all catalysts(0)

News(2)

Report a data issue

comments(0)

VANRAFIA

🐶 often sniffed alongside

targets

all catalysts(0)

News(2)

Report a data issue

comments(0)